RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel
- 8 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Molecular BioSystems
- Vol. 13 (10) , 2125-2134
Abstract
Overcoming chemoresistance will prevent cancer relapse and contribute to clinical chemotherapy. In order to explore the underlying mechanism of chemoresistance, we firstly incubated cancer cells with a combination of cisplatin + paclitaxel (C + P) or cisplatin + paclitaxel + docetaxel (C + P + D) to mimic the treatment of cancer therapy in the laboratory. We found that polyploidy is a recurring strategy that cells adopt in response to cisplatin-based treatments. RNA-sequencing was performed to identify differentially expressed genes (DEGs) that may contribute to drug resistance. 4830 and 5518 DEGs were discovered in C + P and C + P + D resistant cells, respectively, and 4384 (73.40%) genes were shared. Possible drug resistance genes like Atg14, Abcb1b, Tbx2, Slc2a9, Slc10a3 and Slc22a18 were up-regulated while Foxm1, Bcl2, Brca1, Chek1, Hiatl1 and Abcb9 were down regulated. Genes involved in the pathways of p53 signaling, lysosomes and apoptosis were up-regulated, and in contrast, genes in the cell cycle, DNA replication, and mismatch repair pathways were down-regulated. Moreover, representative proteins relative to DEGs were examined to validate the results of RNA-seq and RT-PCR. Taken together, these results will contribute to revealing the mechanism of chemoresistance and discovering potential prognostic factors for cancer medication.Keywords
Funding Information
- Guandong Natural Science Foundation (2014A030313779)
- Guandong Natural Science Foundation (2014A030313779)
This publication has 36 references indexed in Scilit:
- Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell linesEuropean Journal of Pharmacology, 2016
- HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cellsJournal of Ovarian Research, 2016
- Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancerOncotarget, 2015
- Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathwaysTumor Biology, 2015
- MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9Cancer Letters, 2014
- Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-GlycoproteinPLOS ONE, 2012
- Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologiesGynecologic Oncology, 2010
- Selective Resistance of Tetraploid Cancer Cells against DNA Damage‐Induced ApoptosisAnnals of the New York Academy of Sciences, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- DocetaxelDrugs, 2005